Ferriprox is an ‘iron chelator’ (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body. Ferriprox is used: - on its own, when standard iron chelator treatment cannot be used or does not work well enough; - in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat life-threatening conditions (mainly affecting the heart). Ferriprox contains the active substance deferiprone.
Therapeutic Indication
### Therapeutic indication Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Therapeutic Area (MeSH)
N/AATC Code
V03AC02
ATC Item
deferiprone
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Deferiprone | N/A | 去铁酮 |
EMA Name
Ferriprox
Medicine Name
Ferriprox
Aliases
N/ANo risk management plan link.
